Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,988
datasets available to search
ShareScore release 0.9.0
Dataset results
1,988 results for “proliferation”
A CRISPR-Cas9 screen identifies essential CTCF anchor sites for Estrogen Receptor-driven breast cancer cell proliferation
GEO Series GSE124667. Homo sapiens. 28 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Proliferating Langerhans cells dampen inflammation in established mouse psoriatic lesions
GEO Series GSE65309. Mus musculus. 48 samples. Type: Expression profiling by array.
Targeting Mediator MED23 inhibits HCC development by inhibiting compensatory proliferation and promoting ROS-mediated cell death [RNA-Seq]
GEO Series GSE295431. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
MicroRNA-221 promotes cell proliferation and inhibit apoptosis in osteosarcoma cells via directly targeting FBXW11 and regulating the Wnt signaling
<p><strong>Figure 1.</strong> miR-221 expression is significantly high in human clinical tissues and cell lines of OS. The expression levels of miR-221 in 30 pairs of OS tissues and their adjacent, non-cancerous normal bone tissues (Normal) (A) and the human osteoblastic cell line hFOB 1.19 and OS cell lines (B) are detected by qRT-PCR. U6 is used as the internal control. **<em>P</em> < 0.01 and ***<em>P</em> < 0.001.</p> <p><strong>Figure 2. </strong>Attenuating miR-221 expression inhibits OS cell proliferation and increase apoptosis. MiR-221 inhibitor is transfected into MG-63-A16 (A) or U2OS cells (B) and induces an obviously lower proliferation rate compared with that in control groups. Further, miR-221 inhibitor is transfected into MG-63-A16 (C) and U2OS cells (D) and triggers a significantly higher apoptosis than controls. And that, the significantly down-regulated Ki67 expression in MG-63-A16 (E) and U2OS cells (F) were observed compared with that in the controls. **<em>P</em> < 0.01 and ***<em>P</em> < 0.001.</p> <p><strong>Figure 3. </strong>FBXW11 can directly target to miR-221. (A) An potential target of miR-221, called as FBXW11 has been predicted by bioinformatics-based target prediction analysis, and the binding site is on the 3’UTR of FBXW11. (B) RT-PCR analysis of FBXW11 expression in the OS tumor tissues and noncancerous counterparts. (C) The obviously down-regulated expression levels of FBXW11 mRNA are observed in OS cell lines compared with those in hFOB 1.19 cells. (D) A negative Spearman’s correlation between miR-221 and FBXW11 mRNA levels was observed in 30 OS tumor tissues. (E) The significantly decreased luciferase activity driven by 3’UTR of FBXW11 is observed in the miR-211 mimic group and the 3’UTR-MUT group and negative control are as control. (F) The down-regulation of miR-221 induces a dramatic overexpression of FBXW11 protein. (G) A distinctly lower cell proliferation rate is observed in the group of pcDNA-FBXW11 compared with control. (H) An obviously higher apoptosis is observed in the group of pcDNA-FBXW11 than control. (I) The significantly decreased Ki67 expression is detected in the pcDNA-FBXW11 group than control. **<em>P</em> < 0.01 and ***<em>P</em> < 0.001.</p> <p><strong>Figure 4.</strong> miR-221 and FBXW11 regulate cell proliferation and apoptosis in OS through inhibiting Wnt signaling. (A) The markedly down-regulated expression levels of β-catenin, cyclin D1 and c-myc were detected in the group of miR-221 inhibitor compared with controls. (B) The obviously decreased expression levels of β-catenin, cyclin D1 and c-myc were determined in the pcDNA-FBXW11 group compared with controls. **<em>P</em> < 0.01 and ***<em>P</em> < 0.001.</p> <p><strong>Figure 5. </strong>The effect of Wnt signaling on the cell proliferation and apoptosis of OS cell lines. A distinctly lower cell proliferation rate (A and B) and an obviously higher apoptosis rate (C and D) were detected in the Wnt1 siRNA groups (siRNA1, siRNA2) than si-control, and similar results were observed in the CGP049090 group. (E and F) The obviously decreased Ki67 expression were detected in the Wnt1 siRNA groups compared with si-control, and similar results were observed in the CGP049090 group. **<em>P</em> < 0.01 and ***<em>P</em> < 0.001.</p>
Data from: Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis
Platelets modulate the process of cancer metastasis. However, current knowledge on the direct interaction of platelets and tumor cells is mostly based on findings obtained in vitro. We addressed the role of the platelet fibrinogen receptor glycoprotein IIb (integrin αIIb) for experimental melanoma metastasis in vivo. Highly metastatic B16-D5 melanoma cells were injected intravenously into GPIIb-deficient (GPIIb-/-) or wildtype (WT) mice. Acute accumulation of tumor cells in the pulmonary vasculature was assessed in real-time by confocal videofluorescence microscopy. Arrest of tumor cells was dramatically reduced in GPIIb-/- mice as compared to WT. Importantly, we found that mainly multicellular aggregates accumulated in the pulmonary circulation of WT, instead B16-D5 aggregates were significantly smaller in GPIIb-/- mice. While pulmonary arrest of melanoma was clearly dependent on GPIIb in this early phase of metastasis, we also addressed tumor progression 10 days after injection. Inversely, and unexpectedly, we found that melanoma metastasis was now increased in GPIIb-/- mice. In contrast, GPIIb did not regulate local melanoma proliferation in a subcutaneous tumor model. Our data suggest that the platelet fibrinogen receptor has a differential role in the modulation of hematogenic melanoma metastasis. While platelets clearly support early steps in pulmonary metastasis via GPIIb-dependent formation of platelet-tumor-aggregates, at a later stage its absence is associated with an accelerated development of melanoma metastases.
Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
ClinicalTrials.gov study NCT05728268. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
ClinicalTrials.gov study NCT06231680. IPD Sharing: NO. Countries: 1. Publications: 0.
Epiretinal Proliferation in Eyes With Full Thickness Macular Hole
ClinicalTrials.gov study NCT03376776. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Pat
ClinicalTrials.gov study NCT00516880. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Proliferation of Endometrial Stromal Cells in Adenomyosis
ClinicalTrials.gov study NCT00173212. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients
ClinicalTrials.gov study NCT00745225. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
ClinicalTrials.gov study NCT04494061. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging
ClinicalTrials.gov study NCT02486094. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD
ClinicalTrials.gov study NCT06275230. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling
ClinicalTrials.gov study NCT00556244. IPD Sharing: Not stated. Countries: 1. Publications: 0.
D2 Dopamine Receptor on Human Aldosterone-Producing Adenoma and Its Role in Aldosterone Secretion and Cell Proliferation
ClinicalTrials.gov study NCT00173446. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Does Notch Regulate Glioma Proliferation ?
ClinicalTrials.gov study NCT04809597. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Nadolol for Proliferating Infantile Hemangiomas
ClinicalTrials.gov study NCT01010308. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue
ClinicalTrials.gov study NCT03657628. IPD Sharing: NO. Countries: 1. Publications: 0.
OCTA and Retinal Angiomatous Proliferation
ClinicalTrials.gov study NCT04689789. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.